Comparing the Efficacy and Side Effect Profiles of Pazopanib and Sunitinib in the Treatment of Advanced Renal Cell Carcinoma: A Narrative Literature Review Muhammad Faraaz Ismail Abstract Background: Renal Cell Carcinoma (RCC) is the most common form of kidney cancer, accounting for approximately 85% of all kidney malignancies [1, 3].